Related Experiment Video
Updated: May 3, 2026

A High-Throughput Luciferase Assay to Evaluate Proteolysis of the Single-Turnover Protease PCSK9
Published on: August 28, 2018
The hypercholesterolemia-risk gene SORT1 facilitates PCSK9 secretion
Camilla Gustafsen1, Mads Kjolby2, Mette Nyegaard3
1The Lundbeck Foundation Research Center, MIND, Department of Biomedicine, Aarhus University, Vennelyst Boulevard 4, DK-8000 C Aarhus, Denmark.
Abstract:
Circulating PCSK9 destines low-density lipoprotein receptor for degradation in lysosomes, resulting in increased LDL cholesterol. Accordingly, it is an attractive drug target for hypercholesterolemia, and results from clinical trials are promising. While the physiological role of PCSK9 in cholesterol metabolism is well described, its complex mechanism of action remains poorly understood, although it is known to depend on intracellular trafficking. We here identify sortilin, encoded by the hypercholesterolemia-risk gene SORT1, as a high-affinity sorting receptor for PCSK9. Sortilin colocalizes with PCSK9 in the trans-Golgi network and facilitates its secretion from primary hepatocytes. Accordingly, sortilin-deficient mice display decreased levels of circulating PCSK9, while sortilin overexpression in the liver confers increased plasma PCSK9. Furthermore, circulating PCSK9 and sortilin were positively correlated in a human cohort of healthy individuals, suggesting that sortilin is involved in PCSK9 secretion in humans. Taken together, our findings establish sortilin as a critical regulator of PCSK9 activity.
Insights
Sortilin acts as a receptor for PCSK9, a protein that increases LDL cholesterol. This finding reveals a new mechanism regulating PCSK9 secretion and offers potential therapeutic targets for hypercholesterolemia.
Area of Science:
- Molecular Biology
- Biochemistry
- Genetics
Background:
- Circulating PCSK9 promotes LDL receptor degradation, elevating LDL cholesterol levels.
- PCSK9 is a key drug target for hypercholesterolemia, with promising clinical trial outcomes.
- The precise intracellular mechanisms governing PCSK9 activity are not fully understood.
Purpose of the Study:
- To identify novel proteins involved in the regulation of PCSK9 secretion.
- To elucidate the role of sortilin in PCSK9 trafficking and activity.
Main Methods:
- Investigated the interaction between sortilin and PCSK9 using cell biology techniques.
- Utilized sortilin-deficient mice and liver-specific sortilin overexpression models.
- Analyzed the correlation between circulating PCSK9 and sortilin levels in a human cohort.
Main Results:
- Identified sortilin as a high-affinity binding partner for PCSK9.
- Demonstrated that sortilin colocalizes with PCSK9 and facilitates its secretion from hepatocytes.
- Sortilin deficiency in mice reduced circulating PCSK9, while overexpression increased it.
- Observed a positive correlation between circulating PCSK9 and sortilin in humans.
Conclusions:
- Sortilin is a critical regulator of PCSK9 secretion and activity.
- Findings suggest sortilin's involvement in human PCSK9 regulation.
- Establishes a novel molecular pathway influencing cholesterol metabolism.
Related Concept Videos
Pharmacogenomics: Identification of New Drug Targets
Cholesterol: Significance and Regulation
Considering cholesterol and...
Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
Pleiotropy
Regulation of Nuclear Protein Sorting

